growing - deloitte what's...disruption opportunities patients disruption opportunity ecosystem...

Precise Bio is whereregenerative medicine

Growing a completelive & vitalcomplicated organ

meets 3D printing

Anthony Atala MDCo Founder & CMO

W.H. Boyce Professor and Director of the Wake Forest Institute for Regenerative Medicine. He is recognized as a worldwide leader in regenerative medicine and its clinical translation. Dr. Atala is a member of the Institute of Medicine of the National Academy of Sciences, and serves as President of the Regenerative Medicine Foundation.

Aryeh BattCo Founder & CEO

Over 25 years of experience in leading product management and development of cutting edge technology products from research stages to marketing & sales. Aryeh was VP Business and Director of Corporate R&D at Orbotech (Nasdaq: ORBK). Aryeh was VP R&D and then VP BD & CTO at MangoDSP(signal processing). He holds a BSc in Physics and Electro optics engineering from JCT.

Shay Soker PhDCo Founder & CSO

Professor of Regenerative Medicine and Biomedical Engineering at the Wake Forest School of Medicine. Expert in molecular and cellular biology, and natural biomaterials, with more than 18 years experience in tissue and organ engineering. Some of Dr. Soker’s projects have moved to clinical translation while others are being discussed with industry.

Ran MatokiCFO

Over 20 years of Executive Financial roles in North America, Europe and Israel. Ran’s experience includes -$500M in exits, $6.7B in M&As, and $550M in equity funding – from startups to Enterprises. Ran was the CFO of Better Place Israel and prior to that the CFO & COO of Global SAP Partners and Ecosystem division. He is CPA, and Executive MBA (Major in Finance).

Can we grow complicated organsinstead of harvesting them?

Regenerative Medicine meets

3D printing

Engineered Blood Vessel

Cell Technology

Progenitor cells and specific growth factors: expansion potential

1cm2

Day 1 ( 5 x 104 cells)

Day 60 ( 50 x 109 cells)Enough cells to cover a football field

Market Disruption

Market Disruption

Market Disruption

Organ injury due to motor vehicle accident

Pre repair Post repair

First Engineered Organ in Humans: Bladder

Regenerative medicine current challenge

Technology Uniqueness

Ink jet Extrusion Laser Assisted

Resolution 50µm 100µm 1µm

Viscosity Up to 10mPa/s 106mPa/s 106mPa/s

Cell vitality <85% 40-80% >95%

Source: Nature Biotechnology August 2014 Volume 32

Printing of human liver SINGLE cells

The Precise Process

1Sourcing

2Expansion

3 4Deposition

5Maturing

Manual Structuring

Simple Organ

3D Printing

Semi Complex

Organ

Complex Organ

Preparing

Facing Regulation

Expertise Clinical trial Facility

Market Disruption

Cost effective Quality Time

Disruption OpportunitiesPatients

Disruption

Opportunity

ReimbursementsOperationsEcosystem

Affordable, qualitative and time related transplants

Lowering transplants risks and cost

Significantly increasing transplants volume

Curing disease and preventing illness - WW

HMOs, Health InsuranceSurgeons & operations Drs.

Cells expansion, Bio ink, stems cells, Organ imaging

Blue Ocean and higher ‘production possibility frontier’

From saving lives

125Kpeople on the

waiting list in the US

From saving lives

$6Bin the US in Life

saving procedures

To improve quality of life

$100BWorldwide in

all procedures

First Organ – Cardiac Patch

Unmet need | Functional Semi-complex | A-Z manual ‘know how’

• 50% / 5 yrs after MI - Heart Failure

• Remodeling • Cardiac Patch reduces risk and

retrieves functionality

Engineered Heart Valve

Precise Bio is whereregenerative medicine

Growing a completelive & vitalcomplicated organ

meets 3D printing

Thank you

Engineered tissue

BladderBlood vesselBoneCartilageCorneaCorporaDiaphgramEarFasciaFat

HeartHeart valveIntestineKidneyLiverNasal TurbinateNerveOvaryPancreasSalivary glands

Skeletal MuscleSkinSmooth MuscleTendonTestisTracheaUrethraUrinary SphincterUterusVagina